FutureChem Co.Ltd (220100) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FutureChem Co.Ltd (220100) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.43 Billion ≈ $-967.24K USD) by net assets (₩50.88 Billion ≈ $34.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can FutureChem Co.Ltd fund operations to measure how many days the company can operate on defensive assets alone.
FutureChem Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how FutureChem Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
FutureChem Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FutureChem Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
La Française de l'Energie S.A.
PA:FDE
|
0.040x |
|
Castles Technology Co Ltd
TW:5258
|
0.095x |
|
Sea Sonic Electronics Co Ltd
TWO:6203
|
0.076x |
|
Paik Kwang Ind
KO:001340
|
0.021x |
|
SAMG Entertainment Co. Ltd.
KQ:419530
|
-0.006x |
|
Gencor Industries Inc
NYSE MKT:GENC
|
0.052x |
|
Crown Reserve Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CRAC
|
0.000x |
|
Nusatrip Incorporated Common Stock
NASDAQ:NUTR
|
-1.597x |
Annual Cash Flow Conversion Efficiency for FutureChem Co.Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of FutureChem Co.Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 220100 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩54.38 Billion ≈ $36.85 Million |
₩-3.21 Billion ≈ $-2.17 Million |
-0.059x | -1.38% |
| 2023-12-31 | ₩63.91 Billion ≈ $43.31 Million |
₩-3.72 Billion ≈ $-2.52 Million |
-0.058x | +46.36% |
| 2022-12-31 | ₩70.14 Billion ≈ $47.53 Million |
₩-7.61 Billion ≈ $-5.16 Million |
-0.109x | -94.08% |
| 2021-12-31 | ₩52.72 Billion ≈ $35.72 Million |
₩-2.95 Billion ≈ $-2.00 Million |
-0.056x | -6.51% |
| 2020-12-31 | ₩43.37 Billion ≈ $29.39 Million |
₩-2.28 Billion ≈ $-1.54 Million |
-0.052x | +78.37% |
| 2019-12-31 | ₩11.16 Billion ≈ $7.57 Million |
₩-2.71 Billion ≈ $-1.84 Million |
-0.243x | -19.64% |
| 2018-12-31 | ₩16.46 Billion ≈ $11.15 Million |
₩-3.34 Billion ≈ $-2.26 Million |
-0.203x | -94.51% |
| 2017-12-31 | ₩27.20 Billion ≈ $18.43 Million |
₩-2.84 Billion ≈ $-1.92 Million |
-0.104x | -49.37% |
| 2016-12-31 | ₩31.53 Billion ≈ $21.37 Million |
₩-2.20 Billion ≈ $-1.49 Million |
-0.070x | -- |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more